Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| (33 intermediate revisions by 2 users not shown) | |||
| Line 12: | Line 12: | ||
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | * [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | ||
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] | ||
| + | |||
| + | * [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] | ||
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| − | * [[Media: | + | * [[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf|Diffusion-Weighted Magnetic Resonance Imaging (DWI) 2019-12-20]] |
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]] | *[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]] | ||
| Line 30: | Line 32: | ||
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]] | *[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]] | ||
| + | *[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| Atherosclerosis Biomarkers by (C)CTA - Imaging Profile 2020-03-10]] | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']''' | '''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']''' | ||
| − | *[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] (<font color= | + | |
| + | *[[QIBA MSK Profile: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease]] (<font color=##00cc00>'''Vote to release for public comment underway |''' Profile to be published in late June 2020<font>) | ||
| + | |||
| + | *[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf|Dynamic Susceptibility Contrast MRI (DSC-MRI) Profile 2020-01-29]] (<font color=#8b0000>'''closed''' on May 15, 2020<font>) | ||
| + | |||
| + | *[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] (<font color=#8b0000>'''closed''' on February 3, 2020<font>) | ||
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|QIBA US Measurement of Shear Wave Speed for Estimation of Liver Fibrosis Profile 2019-10-21]] ('''closed''' on December 18, 2019) | *[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|QIBA US Measurement of Shear Wave Speed for Estimation of Liver Fibrosis Profile 2019-10-21]] ('''closed''' on December 18, 2019) | ||
| Line 42: | Line 50: | ||
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | QIBA CT Lung Density Profile 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019) | *[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | QIBA CT Lung Density Profile 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019) | ||
| − | :*[[Media:QIBA CT Lung Density Protocols-Appendix | + | :*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|QIBA CT Lung Density Protocols-Appendix E, 2019-06-26]] ('''closed''' on October 16, 2019) |
| − | *[[Media: | + | *[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| QIBA fMRI Profile 2017-06-19]] (''Closed on December 31, 2017'') |
| − | + | '''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font> | |
| − | |||
| − | |||
| − | '''[[Comment Resolutions]]''' are posted for '''Past Public Comments''' and '''Past Technical Confirmations''' . | ||
==Format for Citing Profiles== | ==Format for Citing Profiles== | ||
| Line 59: | Line 64: | ||
: QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles | : QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles | ||
| + | |||
==Statements of Endorsement== | ==Statements of Endorsement== | ||
Revision as of 19:28, 4 June 2020
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Technically Confirmed Profiles
- Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
- Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Please submit comments using the online form
- QIBA MSK Profile: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease (Vote to release for public comment underway | Profile to be published in late June 2020)
- Dynamic Susceptibility Contrast MRI (DSC-MRI) Profile 2020-01-29 (closed on May 15, 2020)
- SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21 (closed on February 3, 2020)
- QIBA US Measurement of Shear Wave Speed for Estimation of Liver Fibrosis Profile 2019-10-21 (closed on December 18, 2019)
- Appendix E: QIBA US SWS Checklists for Implementation of the SWS Profile, 2019-10-21 (closed on December 18, 2019)
- QIBA CT Lung Density Profile 2019-09-03 (Contains Conformance Checklist, Appendix B) (closed on October 16, 2019)
- QIBA CT Lung Density Protocols-Appendix E, 2019-06-26 (closed on October 16, 2019)
- QIBA fMRI Profile 2017-06-19 (Closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL
Example:
- QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)